Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

01-02-2015 | Original Article E-learning | Uitgave 2/2015 Open Access

Netherlands Heart Journal 2/2015

Left ventricular assist device for end-stage heart failure: results of the first LVAD destination program in the Netherlands

Tijdschrift:
Netherlands Heart Journal > Uitgave 2/2015
Auteurs:
M. L. A. Haeck, S. L. M. A. Beeres, U. Höke, M. Palmen, L. E. Couperus, V. Delgado, E. A. Logeman, J. J. Maas, R. J. M. Klautz, M. J. Schalij, H. F. Verwey
Belangrijke opmerkingen
The questions can be answered after the article has been published in print. You have to log in to: www.​cvoi.​nl.

Abstract

Purpose

Mechanical circulatory support with a continuous-flow left ventricular assist device (LVAD) may be a valuable treatment in end-stage heart failure patients for an extended period of time. The purpose of this study was to evaluate the safety and efficacy of implantation of a continuous-flow LVAD in end-stage heart failure patients within the first destination program in the Netherlands.

Methods

A third-generation LVAD was implanted in 16 heart failure patients (age 61 ± 8; 81 % male; left ventricular ejection fraction 20 ± 6 %) as destination therapy. All patients were ineligible for heart transplant. At baseline, 3 and 6 months, New York Heart Association (NYHA) functional class, quality-of-life and exercise capacity were assessed. Clinical adverse events were registered.

Results

Survival at 30 days and 6 months was 88 and 75 %, respectively. In the postoperative phase, 6 (38 %) patients required continuous veno-venous haemofiltration for renal failure and 2 (13 %) patients required extracorporeal membrane oxygenation because of severe right ventricular failure. During follow-up, NYHA functional class and quality-of-life improved from 3.7 ± 0.1 to 2.3 ± 0.1 and 57 ± 5 to 23 ± 3 at 6 months (P < 0.001), respectively. The 6 min walking distance improved from 168 ± 42 m to 291 ± 29 m at 6 months (P = 0.001).

Conclusion

Continuous-flow LVAD therapy is a promising treatment for patients with end-stage heart failure ineligible for heart transplant.

Onze productaanbevelingen

Netherlands Heart Journal

Het Netherlands Heart Journal wordt uitgegeven in samenwerking met de Nederlandse Vereniging voor Cardiologie en de Nederlandse Hartstichting. Het tijdschrift is Engelstalig en wordt gratis beschikbaa ...

Literatuur
Over dit artikel

Andere artikelen Uitgave 2/2015

Netherlands Heart Journal 2/2015 Naar de uitgave